Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague-Reference-Cited by-同舟云学术

Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague

Published:2021-09-02 Issue:2 Volume:88 Page:416-428
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Nguyen Dung¹,Shaik Jafar Sadik¹,Tai Guoying¹,Tiffany Courtney¹,Perry Caroline¹,Dumont Etienne¹,Gardiner David¹,Barth Aline¹,Singh Rajendra¹,Hossain Mohammad¹

Affiliation:

1. GlaxoSmithKline Collegeville PA United States

Funder

Biomedical Advanced Research and Development Authority

GlaxoSmithKline

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.14996

Reference56 articles.

1. World Health Organization.Antibiotic Resistance. November 2017.http://www.who.int/mediacentre/factsheets/antibiotic-resistance/en/Accessed 7 March 2018.

2. In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens

3. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase

4. Type IIA topoisomerase inhibition by a new class of antibacterial agents

5. P2.38 Microbiological analysis from a phase II study in adults evaluating single doses of gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea caused by Neisseria gonorrhoeae;Scangarella‐Oman N;Sex Transm Infect,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants;British Journal of Clinical Pharmacology;2024-06-10

2. Gyrase and Topoisomerase IV: Recycling Old Targets for New Antibacterials to Combat Fluoroquinolone Resistance;ACS Infectious Diseases;2024-04-02

3. Translational PK/PD for the Development of Novel Antibiotics—A Drug Developer’s Perspective;Antibiotics;2024-01-11

4. Regulatory Requirements and Applications of Physiologically Based Pharmacokinetic Models;ADME Processes in Pharmaceutical Sciences;2024

5. Application of pediatric-adapted modeling and simulation approaches;Essentials of Translational Pediatric Drug Development;2024